Biomarker-Based CIN Risk Prediction in CKD Patients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting contrast-induced nephropathy (CIN) are delayed and ineffective, particularly in patients with chronic kidney disease (CKD), lacking early detection capabilities and effective preventive strategies.
Innovation Solution
A method involving the determination of L-FABP and NGAL biomarker concentrations in serum samples, combined with statistical analysis, to predict the risk of CIN and inform timely interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If creatinine is used as a biomarker for detecting AKI, then the detection is simple and widely available, but the detection is delayed and poor at early detection of acute tubular necrosis
Solution Approach 1:
The patent measures biomarker levels (NGAL, L-FABP, KIM-1, IL-18) before contrast media administration to establish baseline levels, enabling early detection of AKI risk before the condition fully develops. This preliminary measurement approach allows for proactive identification of patients at risk, addressing the detection delay inherent in using creatinine alone.
Solution Approach 2:
The patent introduces multiple intermediate biomarkers (NGAL, L-FABP, KIM-1, IL-18) that serve as mediators between the initial renal injury and the final creatinine elevation. These biomarkers appear in the blood stream earlier than creatinine, providing an intermediate detection signal that bridges the gap between early injury and late creatinine-based diagnosis.
2Measurement precision
If multiple biomarkers are measured to improve early detection accuracy, then the prediction accuracy improves, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent combines multiple biomarker measurements (NGAL, L-FABP, KIM-1, IL-18) into a single integrated diagnostic approach. By measuring all these markers together and analyzing their combined patterns, the patent achieves high prediction accuracy while managing complexity through a unified testing protocol rather than separate sequential tests.
Solution Approach 2:
The patent monitors changes in biomarker levels from baseline (pre-contrast) to post-contrast time points. By focusing on the dynamic changes rather than absolute values, and by using statistical analysis to interpret these changes, the patent simplifies the interpretation process while maintaining high predictive accuracy for CIN risk.
3Reliability
If preventive strategies are implemented early to reduce CIN risk, then the morbidity and hospital stay are reduced, but the cost and resource utilization increase
Solution Approach 1:
The patent applies preventive strategies selectively to patients identified as high-risk through biomarker analysis, rather than universally to all patients. By concentrating resources on the specific subgroup of patients who show elevated biomarker levels indicating CIN risk, the patent improves patient outcomes for those who need intervention most while avoiding unnecessary resource utilization in low-risk patients.
Solution Approach 2:
The patent uses biomarker measurements to provide feedback on individual patient risk status, which then guides the application of preventive strategies. This feedback mechanism ensures that preventive resources are allocated based on actual patient need as indicated by objective biomarker data, optimizing the balance between outcome improvement and resource utilization.
Data Source
Figure 1
Figure 2a~2e
Figure 3
AI summary
The use of biomarkers for establishing risk of developing contrast-induced nephropathy (CIN) in patients with pre-existent chronic kidney disease (CKD) is described.